ATE539757T1 - Verfahren zur hemmung von nkt-zellen - Google Patents

Verfahren zur hemmung von nkt-zellen

Info

Publication number
ATE539757T1
ATE539757T1 AT05851383T AT05851383T ATE539757T1 AT E539757 T1 ATE539757 T1 AT E539757T1 AT 05851383 T AT05851383 T AT 05851383T AT 05851383 T AT05851383 T AT 05851383T AT E539757 T1 ATE539757 T1 AT E539757T1
Authority
AT
Austria
Prior art keywords
nkt cell
treatment
nkt cells
inhibiting
galactosylceramide
Prior art date
Application number
AT05851383T
Other languages
English (en)
Inventor
Samuel Strober
Everett Hurteau Meyer
Dale T Umetsu
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE539757T1 publication Critical patent/ATE539757T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05851383T 2004-11-02 2005-11-02 Verfahren zur hemmung von nkt-zellen ATE539757T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62456804P 2004-11-02 2004-11-02
US70654805P 2005-08-08 2005-08-08
PCT/US2005/040182 WO2006060117A2 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Publications (1)

Publication Number Publication Date
ATE539757T1 true ATE539757T1 (de) 2012-01-15

Family

ID=36565493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851383T ATE539757T1 (de) 2004-11-02 2005-11-02 Verfahren zur hemmung von nkt-zellen

Country Status (11)

Country Link
US (2) US7682614B2 (de)
EP (1) EP1812015B1 (de)
JP (1) JP4948418B2 (de)
CN (1) CN101031307B (de)
AT (1) ATE539757T1 (de)
AU (1) AU2005310247A1 (de)
CA (1) CA2584971C (de)
DK (1) DK1812015T3 (de)
ES (1) ES2378076T3 (de)
PT (1) PT1812015E (de)
WO (1) WO2006060117A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441893C (en) 2001-03-26 2015-01-20 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
EP2575824A4 (de) * 2010-05-24 2014-02-19 Childrens Medical Center Verfahren zur behandlung und vorbeugung von entzündungskrankheiten
RU2603075C2 (ru) * 2010-11-25 2016-11-20 Имнейт Сарл Изменение иммуногенности антигена путем введения эпитопов, узнаваемых nkt-клетками
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
EP2755688A4 (de) * 2011-10-27 2014-08-06 Nkt Therapeutics Inc Humanisierte antikörper gegen inkt
EP2906576B1 (de) 2012-10-12 2019-09-11 The Brigham and Women's Hospital, Inc. Glycosphingolipide und verfahren zur verwendung davon
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
MX386714B (es) 2015-01-27 2025-03-11 Lava Therapeutics N V Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
WO2018014012A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
JP7457007B2 (ja) 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用ＣＤ１ｄ免疫グロブリン
EP4301374A4 (de) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc Verbindungen zur aktivierung invarianter natürlicher killer-t-zellen und verfahren zur verwendung bei der beseitigung entzündlicher alternder zellen
WO2022183562A1 (zh) * 2021-03-03 2022-09-09 东莞市东阳光冬虫夏草研发有限公司 一类葡萄糖脑苷脂化合物、其药物组合物及其用途
EP4480486A1 (de) * 2022-02-14 2024-12-25 Riken Nkt-zellen-ligandhaltige liposomzusammensetzung

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US7063844B2 (en) * 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5679347A (en) * 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
DK0751780T3 (da) 1993-06-21 2003-10-13 Brigham & Womens Hospital Fremgangsmåder til isolering af CD1-fremviste antigener, vacciner, som omfatter CD1-fremviste antigener, og cellelinier til anvendelse i nævnte fremgangsmåder
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
EP1520583B1 (de) * 1997-04-10 2009-01-28 Kyowa Hakko Kirin Co., Ltd. NKT-Zellenaktivatoren, die Alpha-Glycosylceramide enthalten
EP1011719A1 (de) * 1997-09-12 2000-06-28 Brigham & Women's Hospital Synthetische antigene zur cd-1 beschränkte immunantwort
TW575420B (en) * 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
JP2003524146A (ja) 1998-07-09 2003-08-12 ニッコロフ，ブライアン・ジェイ Ｔ細胞上のナチュラルキラーレセプターとそれらに対応するリガンドとの相互作用を変調することにより疾患を治療する方法
US20010051156A1 (en) * 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
US20020071842A1 (en) * 2000-06-05 2002-06-13 Gumperz Jenny E. Soluble CD1 compositions and uses thereof
CN1444648A (zh) * 2000-06-06 2003-09-24 麒麟麦酒株式会社 扩增自然杀伤t细胞的方法
EP1297017B1 (de) * 2000-06-19 2012-06-13 Beth Israel Deaconess Medical Center Verwendungen und zusammensetzungen von monoklonalen oder polyklonalen antikörpern, die spezifisch für t-zell subpopulationen sind
WO2001098317A2 (en) * 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
JP3986957B2 (ja) * 2000-08-18 2007-10-03 三菱電機株式会社 ランプ用トランス
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
IL140537A0 (en) * 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
CA2441893C (en) * 2001-03-26 2015-01-20 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US6662434B2 (en) * 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
WO2002087556A2 (en) * 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20020171538A1 (en) * 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) * 2001-05-18 2002-11-21 Wegener William E. Security electronic system
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
WO2003092615A2 (en) 2002-05-01 2003-11-13 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
WO2003105769A2 (en) * 2002-06-13 2003-12-24 New York University Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
ATE549064T1 (de) 2002-06-14 2012-03-15 Us Gov Health & Human Serv Verfahren zur behandlung und prävention von kolitis, die il-13 und nk-t zellen betrifft
US7368142B2 (en) * 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
EP1539095A1 (de) 2002-08-27 2005-06-15 Société des Produits Nestlé S.A. Prävention oder behandlung von epithelgewebeschäden oder haarausfall
AU2003277021A1 (en) 2002-09-27 2004-04-19 Biomira, Inc. Glycosylceramide analogues
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040171522A1 (en) * 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en) * 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20050032210A1 (en) * 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
US20040235162A1 (en) * 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
WO2004094444A1 (en) * 2003-03-20 2004-11-04 Brigham Young University 6'-amino-6'-deoxygalactosylceramides
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
EP1653977A2 (de) 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Behandlung von erkrankungen im zusammenhang mit natürlichen killer-t-zellen
EP1767216B1 (de) * 2004-06-11 2012-07-11 Riken Arzneimittel mit regulierendem zellliganden in einem liposom

Also Published As

Publication number Publication date
AU2005310247A1 (en) 2006-06-08
CN101031307B (zh) 2012-09-05
JP4948418B2 (ja) 2012-06-06
EP1812015A2 (de) 2007-08-01
PT1812015E (pt) 2012-02-20
EP1812015B1 (de) 2012-01-04
US7682614B2 (en) 2010-03-23
ES2378076T3 (es) 2012-04-04
US20100197613A1 (en) 2010-08-05
WO2006060117A2 (en) 2006-06-08
CA2584971C (en) 2013-08-06
WO2006060117A3 (en) 2007-03-01
EP1812015A4 (de) 2008-02-20
DK1812015T3 (en) 2013-01-02
US20060116332A1 (en) 2006-06-01
CA2584971A1 (en) 2006-06-08
JP2008518974A (ja) 2008-06-05
CN101031307A (zh) 2007-09-05
US8679499B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
EP1812015A4 (de) Verfahren zur hemmung von nkt-zellen
BR112014018210A2 (pt) moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
BR112013026114A2 (pt) composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
WO2008137758A3 (en) Amino acid lipids and uses thereof
Soares et al. Oleanolic acid promotes orofacial antinociception in adult zebrafish (Danio rerio) through TRPV1 receptors
Kern et al. Tick saliva represses innate immunity and cutaneous inflammation in a murine model of Lyme disease
EA201000424A1 (ru) Антитела к il-23
EA200501592A1 (ru) Способы и композиции для введения агонистов trpv1
MA41521A1 (fr) Nouveaux épitopes de cellules et nouvelle combinaison d'épitopes de cellules destinés à être utilisés dans l'immunothérapie du myélome et d'autres cancers
BR112018003316A2 (pt) compostos e métodos para entrega transmembrana de moléculas
MA46648A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
MA35450B1 (fr) Molécules de liaison pour bcma et cd3
BR112015014372A8 (pt) inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas".
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
EA200802167A1 (ru) Лекарства и применения
WO2009075774A3 (en) Glycosaminoglycan-coated particles and uses thereof
MX2009002787A (es) Composiciones y métodos para prevenir el cáncer con cupredoxinas.
Meijlink et al. 6 ″-Modifed α-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria
BR112014028997A2 (pt) formulações estabilizadas contendo anticorpos anti-dll4